Partner's Blog - April 2020

Dear Valued Member:

So much has changed since the AST’s Cutting Edge of Transplantation (CEoT) meeting last month, but I would be remiss not to mention the meeting’s success and how grateful we were of the opportunity to meet with some of our partners before this pandemic.

All of us at the AST appreciate the response you have taken to provide resources to transplant patients since the outbreak of COVID-19, reflected in your posts below. The AST is also committed to providing the most current information to the transplant community and continues to build upon the COVID-19 Resources Page. This page includes FAQ documents for both transplant professionals and recipients, as well as additional resources from other organizations and agencies.

Thanks to our Corporate Partners for providing the following information on how they are responding to this crisis. During this critical time, it’s important we adjust accordingly to ensure we are meeting our patients’ needs.

Anil Chandraker, MD, FASN, FRCP
AST Development Chair

View all updates

The Corporate Affiliates Program provides an exciting opportunity for companies to support the work of the American Society of Transplantation (AST) and receive tangible benefits throughout the year. The following companies are members of the 2020 Corporate Affiliate Program (CAP):

What's News With Our Partners:

In response to the COVID-19 crisis, CareDx has launched RemoTraC: Home-based blood draws for transplant patients. RemoTraC is available to all patients who want their transplant monitoring lab tests to be drawn from the comfort of their home by trained mobile phlebotomists. RemoTraC includes AlloSure and/or AlloMap, CareDx’s surveillance tests, along with a panel of routine tests. CareDx will fully cover the cost of the mobile phlebotomist and will ensure no additional out-of-pocket expenses beyond what is typically paid for these tests. For more information contact your local transplant account manager or visit http://www.caredx.com/remotrac.

CSL Behring Update: GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY READ MORE

Mallinckrodt Submits New Drug Application to FDA for Terlipressin READ MORE

In the midst of the COVID-19 pandemic, Natera continues to provide remote access of its Prospera transplant assessment test to kidney transplant patients without requiring live office visits. Testing can be fulfilled remotely by transplant clinicians, delivered at the push of a button with virtual ordering and remote blood draws in the comfort and safety of a patient's home. The remote functionality is fulfilled through Natera's online platforms and a nationwide mobile blood draw network that performed roughly 10,000 in-home draws in 2019. READ MORE
Natera recently received final Medicare coverage for the Prospera donor-derived cell-free DNA (dd-cfDNA) test, available for all kidney transplant recipients. The Prospera test assesses the risk of active renal allograft rejection with greater precision than other biomarkers or other dd-cfDNA tests on the market. Prospera is the industry's first dd-cfDNA test clinically validated to identify both T-cell mediated rejection and antibody mediated rejection. READ MORE